Other Events

< 2020 >
September
Sun
Mon
Tue
Wed
Thu
Fri
Sat
August
August
1
2
  • Sep 2-Sep 4: Virtual conference
    All day
    2020.09.02-2020.09.04

    Big retailers like Walmart quietly moving to insurance business in their latest move into healthcare

    With the surge in demand for health insurance in recent months due to the COVID-19 crisis, big-box retailers such as Walmart are slowly making their movies in the healthcare and insurance business. (Article credit: CNBC.com)

    Join the virtually at Asia Healthcare Week this 2 – 4 September 2020 as healthcare and insurance experts share their views on the re-engineering of health insurance products and business models and the impact of digitalisation surrounding this COVID-19 risk management.

  • 9月2日至9月4日:虚拟会议
    All day
    2020.09.02-2020.09.04

    像沃尔玛这样的大零售商在医疗改革的最新举措中悄悄地转向保险业务

    近几个月来,由于COVID-19危机,医疗保险需求激增,沃尔玛等大型零售商正在慢慢在医疗和保险业务领域拍电影。 参加2020年9月2日至4日的亚洲医疗周,医疗保健和保险专家就健康保险产品和商业模式的重新设计以及围绕COVID-19风险管理的数字化影响分享他们的观点。

  • 9月2日-9月4日:细胞产业大会 2020 第五届(上海)细胞与肿瘤精准医疗高峰论坛
    All day
    2020.09.02-2020.09.04

    近几年来,国内外各个国家均将细胞治疗和精准医疗作为医疗领域重点支持和发展的项目,我国也制定了一系列加快生物医药产业发展的方针和政策,以满足市场对于新型治疗产品和技术的需求。随着国内开展的细胞和基因治疗临床研究逐渐增加,对于细胞治疗产品产业化及新产品尽快应用于临床的需求也越来越高 。

    第五届(上海)细胞与肿瘤精准医疗高峰论坛,专业人士齐聚一堂,分享研究成果、最新技术,同时探讨细胞产业发展面临的困境及未来发展动向,推动细胞治疗和精准医疗产品的市场化进程。

    点击查看详情

    关键词:细胞存储与治疗、肿瘤细胞免疫治疗、干细胞治疗、CAR-T、再生医学、细胞治疗产品注册与申报、创新药研发、PD-1/L1药物、早筛早诊、肿瘤的转移和复发监测、肿瘤的分子靶向治疗、靶向用药、单细胞测序、NGS技术引领下的基因组科学与技术、数字PCR、质谱、PCR衍生技术、精准医疗产业化进程、分子诊断、基因治疗、基因测序、核酸检测、液体活检及肿瘤早筛、肿瘤全周期、肿瘤临床治疗、基因组学、生物标志物、转化医学、生物制品、生物信息大数据、AI辅助诊断、体外诊断、抗体、MALBAC技术、Crispr/Cas9和基因编辑技术、实验室管理与控制、临床应用与研究、肿瘤用药基因检测、政策监管、组学大数据、产业集群化、产业现状分析与展望。

3
  • September 3-September 4: Pharmaceutical R&D Innovation Forum
    All day
    2020.09.03-2020.09.04

    September 3-September 4
    Location: Beijing

    Mr. Kun Liu, Executive Vice President of New Leaders, will make a keynote speech on “Beyond Technology – Customer Communication and Service in R&D Companies”. “Industrialization”. Research work related to industrialization (including technology and registration) requires full communication and close cooperation between R&D units and pharmaceutical companies in order to achieve it.
    In the collaboration process, a large part of what affects the progress and quality of project development is not the technical factor, but the communication factor. Efficient communication can greatly improve the project achievement and success rate. Under the new situation, establishing a strategic partnership is the safest and most effective way of cooperation between pharmaceutical companies and R&D units.
    The speaker will share the above content based on our company’s years of experience and the development of the industry.

    Read more

  • 9月3日至9月4日:医药研发创新论坛
    All day
    2020.09.03-2020.09.04

    9 月 3 日至 9 月 4 日
    地点: 北京

    新领袖执行副总裁刘坤先生将作题为”超越技术——研发公司的客户沟通与服务”的主旨演讲。 “工业化”。 与工业化有关的研究工作(包括技术和注册)需要研发单位与制药公司充分沟通和密切合作才能实现。
    在协作过程中,影响项目开发进度和质量的很大一部分不是技术因素,而是沟通因素。 高效的沟通可以大大提高项目的成绩和成功率。 在新的形势下,建立战略伙伴关系是制药公司与研发单位之间最安全、最有效的合作方式。
    演讲者将分享上述内容的基础上,我们公司的多年经验和行业的发展。

    Read more

    北京新领先医药科技发展有限公司为国内最大的全产业链CRO公司之一。公司成立于2005年1月,注册资本9155.42万元,于2015年通过重组实现主板上市(股票代码:600222)。创建十六年以来,北京新领先在药学研究、临床CRO研究、IVIVR体内外桥接研究和药品进出口注册等领域,一直处于行业领先地位,并连续四年(2017-2020年)被评为“中国医药研发公司10强”(2020年位居榜首)。目前,公司已经和国内外300多家医药企业建立起了合作关系,成功承接了400个余项仿制药品种的药学研发、近500个项目的临床研究,申请专利近100项,获得授权近50项。2020年,新领先依托既有的技术和管理团队,整合郑州临空生物园平台,全面入资,建设并运营了六大技术平台,包括新药筛选及检测平台、药物评价平台(动物房)、大分子中试及商业化生产服务平台(大分子CDMO)、小分子CMC研究及商业化生产服务平台(小分子CDMO)、细胞治疗技术服务平台和临床CRO服务平台,覆盖临床前及CMC研发、委托加工、临床CRO、申报注册及MAH委托质量管理等药品生命全周期,为全球客户提供真正意义上的一站式服务。

4
  • 千呼万唤:广州国际康复设备展于9月4日开展!
    All day
    2020.09.04

    预计9月份国内的疫情已经得到很好的控制,世界的疫情形势也将平稳。 在这个时间段举办展会,必将是今年国内首批全国性的康复展,作为十年具有较高知名度的康复展品牌,疫情后的康复行业风向变化几何,整个康复产业的生态环境、发展前景又将迎来怎样的革新,都将能够在本届广州国际康复设备展中一探究竟。

    随着政府、群众的康复意识不断增强,康复医学发展也随之越来越受到重视,发展空间不断扩大:社区康复、家庭康复的建设成了重中之重的任务,而对福祉辅具、家用医疗康复设备的需求也将会迎来喷发式的增长 。

5
  • 9月5日:2020年高通量临床质谱应用论坛
    8:30 am-5:30 pm
    2020.09.05

    为探讨临床质谱的未来,由杭州市高新区(滨江)协会和杭州汇健科技有限公司主办的”2020高通度临床质谱技术与应用论坛”。 会议旨在弥合学术界、临床专家、质谱仪器制造商和临床质谱仪施用者之间的差距。将邀请学术界、临床医学和质谱学界的专家就组织学和分子医学的研究前沿、高通量临床质谱技术与产业化、质谱学技术的临床应用以及质谱仪器的国产化之路进行探讨和交流。
    Read more

    质谱技术在蛋白组学和代谢组学研究中发挥着重要的作用,越来越多与人类疾病相关的蛋白质和代谢标志物已经被发现和验证。然而,质谱技术在临床检验中的应用才初露端倪,组学诊断在精准医疗领域的实际应用还有巨大的空间。推动质谱技术从科研走向临床,构建质谱产业生态链至关重要。

  • September 5: 2020 Forum on the Application of High-throughput Clinical Mass Spectrometry
    8:30 pm-5:30 pm
    2020.09.05

    To discuss the future of clinical mass spectrometry, the “2020 High-Throughput Clinical Mass Spectrometry Technology and Application Forum”, co-organized by Hangzhou High-Tech Zone (Binjiang) Association and Hangzhou Huijian Technology Co. The conference aims to bridge the gap between academia, clinical experts, mass spectrometry instrument manufacturers, and clinical mass spectrometry applicators.Experts from academia, clinical medicine, and mass spectrometry industry will be invited to discuss and exchange ideas on the research frontiers of histology and molecular medicine, high-throughput clinical mass spectrometry technology and industrialization, clinical application of mass spectrometry technology, and the road to localization of mass spectrometry instruments.
    Read more

6
7
8
9
  • 9月9-11日:第22届上海国际生物技术与医药研讨会(BIO-FORUM 2020)
    All day
    2020.09.09-2020.09.11

    强化科技创新策源功能,引领生物医药产业发展

    600+行业精英 6大活动版块 8大专题分会

    “上海国际生物技术与医药研讨会”(BIO-FORUM)举办22 届以来,始终聚焦生物医药创新发展,持续得到上海市科学技术委员会、上海市发展改革委、上海市药品监督管理局、上海市经济和信息化委员会、上海市卫生健康委员会等相关委办的大力支持,已成为全国生物医药领域最具规模和品牌效应的综合性国际研讨会。“第 22 届上海国际生物技术与医药研讨会(BIO-FORUM 2020)” 由上海市生物医药科技产业促进中心(上海新药研究开发中心)和徐汇区科学技术委员会共同主办,将于 2020 年9 月9-11 日以线上线下多维互动的方式举办,开幕式将于9 月10 日上午9 : 00 在主会场上海中星铂尔曼大酒店(徐汇区浦北路 1 号)正式召开。

    本届大会将以“强化科技创新策源功能,引领生物医药产业发展”为主题,聚焦行业和社会热点,体现上海科技抗疫成果,并结合线上直播、云展厅等多种形式,打造BIOFORUM2020 云峰会。大会将邀请来自生物技术与医药领域的国内外知名学者、企业高层以及政府监管机构、风险投资等领域的专家出席,就抗体药物、生物样本库及人类遗传资源、细胞治疗、新冠病毒治疗药物和疫苗开发、生物医药创新以及生物医学工程等内容进行深入交流、研讨。大会将由会前会、卫星会、开幕式、主旨演讲、专题分会、一对一配对、同期展览(云展厅)等多个活动组成。

    详情及报名点击这里

  • Sep 9:Spinning out a cancer immunotherapy startup – The Story of PairX Bio
    11:00 am-12:00 pm
    2020.09.09

    TopicSpinning out a cancer immunotherapy startup – The Story of PairX BioDescriptionSingapore has a thriving ecosystem of scientists, investors and funding agencies committed to promoting Bio-entrepreneurship in the life science sector. One such exciting space is the SingHealth Duke-NUS Academic Medical Centre (AMC), where innovation and entrepreneurship comes alive. In this webinar, we will feature the story of PairX Bio (“PairX”), a new Singapore-based Biotech Company in cancer immunotherapy and latest spin off from Duke-NUS AMC. The panel featuring Dr Raymond Lee, scientific co-founder of PairX; Mr XQ Lin, an investor in PairX; and Ms Cheryl McCaffery, Director of Duke NUS’ commercialization office, will share their insights on the opportunities and challenges of starting a biotech company. We invite you to join us in the first of our Bio-entrepreneurship series with Duke-NUS and learn more about exciting innovations in Singapore’s Biotech ecosystem.Time

    Sep 9, 2020 11:00 AM in Singapore

    RSVP here.

10
  • 9月10-11日:2020大健康产业高质量发展大会暨第五届中国医药研发•创新峰会
    All day
    2020.09.10-2020.09.11

    9月10日-11日,由中国药科大学、中国医药企业管理协会、重庆市经济和信息化委员会、重庆经济技术开发区管理委员会、重庆市南岸区人民政府、重庆药学会指导的,药智网、中国药业杂志社、中国药房主办的“2020大健康产业高质量发展大会暨第五届中国医药研发•创新峰会(PDI)”前幕开启,今日(9月9日)已开始签到,峰会会务组欢迎您的到来!

    本次峰会以“制剂创新,引领未来”为主题,邀请100+专家学者、政府领导,300+参会医药企业,参会人数将达到上千人。

    详情及报名点击这里

  • 9月10日:2020单细胞测序技术应用论坛
  • 9月10日:从初创到IPO,生物医药企业如何做好企业财务管理
    2:00 pm-5:00 pm
    2020.09.10

    为了帮助初创企业更好的了解企业IPO需要注意的财务管理信息,提早为IPO做好准备,天科雅与广东医谷、丹麓资本共同举办本次“生物医药企业从初创到IPO的财务管理要点”分享会,与大家共同探讨生物医药企业从初创到IPO的财务管理要点,欢迎企业CEO及财务负责人报名参加。

    活动时间:2020年9月10日(星期四)下午14:00-17:00

    活动地点:南沙区南江二路6号广东医谷南沙产业园1号楼4楼会议室

    报名方式:报名免费,请在“活动行”报名,在活动开始前一天将会收到地址短信(请注意查收)

    主办单位:丹麓资本 广东医谷  广东天科雅生物医药科技有限公司

    嘉宾:

    胡洋,中山大学生物化学与分子生物学博士,现任广发证券投资银行部医疗健康行业群组高级副总裁,首席行业专家。曾在《Molecular Cell》、《Scientific Reports》等国际期刊发表研究论文,具有扎实的生物专业理论背景,具备丰富的生物医药行业公司研究经验,在广发证券主要负责医疗健康行业公司的IPO、并购、再融资等投行业务,曾参与百奥泰、宏达电子、泰宝医疗、万孚生物、康辰药业等IPO、再融资及并购重组项目,具有丰富的运作经验和广泛的行业资源。

    金春丽,芝加哥大学MBA,2018年1月加入华领医药担任财务总监,成功带领会计及财务计划部门完成香港联交所证券上市准备并且维护联交所上市后的披露要求。在加入华领医药之前,金春丽任职安永华明会计师事务所,带领审计团队协助审计客户完成美国证券市场上市和香港证券市场上市及上市后的财务审计工作。

    详情及报名点击这里

11
  • SEP 11: Biological Clocks and Other Biomarkers of Aging in Regulatory Development
    11:30 am-12:30 pm
    2020.09.11

    The Role of Biological Clocks and Other Biomarkers of Aging in Regulatory Development

    About this Event

    The explosion of research and development of biological clocks and other biomarkers of aging is beginning to guide an array of activities from drug discovery to medical care to personal wellness to the commercialization of nutritional supplements. Despite their recent perfusion into numerous fields, aging biomarkers have yet to play a meaningful role in regulatory development. Key reasons for this include the fact that aging is not currently a disease or condition within the purview of the FDA and that the elevation of biomarkers to surrogate markers that can support registration typically takes decades of emerging scientific consensus. Particularly in the case of aging biomarkers, very large, very long validating clinical trials may be necessary. However, cross-silo attention on validating aging biomarkers could accelerate the development of agents that prevent or delay chronic diseases associated with aging.

    Join our “dream team” expert panel, consisting of the discoverer of the DNA methylation epigenetic clock, developer of a biological clock that supports commercialization of an anti-aging supplement, one of the top thought leaders from the FDA, the chief scientist for an AI-based company commercializing aging and longevity clocks, and the Scientific Director from the National Institute on Aging as they discuss the history, current status and future directions of biomarkers of aging as well as their potential role in regulatory development of interventions for the prevention or delay of chronic diseases and the extension of healthspan.

    About the Speakers

    Steve Horvath, PhD, ScD, is a Professor in Human Genetics and Biostatistics Departments of the Geffen School of Medicine at UCLA. His research draws from numerous fields, including epidemiology, epigenetics, and systems biology, to develop novel approaches to researching a broad spectrum of age-related diseases like cancer, neurodegenerative disease, and cardiovascular disease. An acknowledged leader within genetics and biostatistics fields, Dr. Horvath developed the epigenetic clock, a versatile biomarker that utilizes DNA methylation levels to measure biological age across multiple DNA sources. Dr. Horvath also developed the weighted gene co-expression network analysis, a data mining technique used especially in studying biological networks.

    Morgan Levine, PhD, is a Professor within the Department of Pathology at the Yale School of Medicine. Her work incorporates multiple theories and methodologies from statistical genetics, computational biology, and mathematical demography to uncover measures for aging as well as risk stratification for major chronic diseases such as cancer and Alzheimer’s. Dr. Levine also serves as the Head of Bioinformatics at Elysium Health, a company that incorporates recent scientific developments in aging into its production of dietary supplements. In this capacity, she led the development of Elysium’s Index, an at-home test that measures an individual’s cumulative rate of aging.

    Robert Temple, MD, currently serves as Deputy Center Director for Clinical Science at the FDA’s Center for Drug Evaluation and Research (CDER) as well as Senior Advisor in the Immediate Office of the Office of New Drugs (OND). A long-time member of the FDA, Dr. Temple has held numerous positions within the agency spanning back to 1972, including a 23-year tenure as the Acting Deputy Director of OND’s Office of Drug Evaluation-I, which regulates cardiovascular, renal, neurological, and psychiatric drug products. Dr. Temple’s primary interests lie in the design and conduct of clinical trials, as he has written extensively on topics relating to study enrichment and issues related to study design and interpretation.

    Polina Mamoshina, PhD, is chief scientist at Deep Longevity, a spin-off of AI leader Insilico Medicine, that develops and commercializes aging and longevity clocks. She previously served as a Head of Biomarker Development at Insilico Medicine. Dr. Mamoshina’s primary research interests lie in artificial intelligence, deep learning, and biomarkers of aging, disease, and drug responses. Her expertise has led to her involvement in multiple deep learning projects with Insilico’s Pharmaceutical Artificial Intelligence Division such as the development of their drug discovery engine as well as biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of aging and disease.

    Luigi Ferrucci, MD, PhD, currently serves as the National Institute on Aging’s Scientific Director and Chief of the Longitudinal Studies Section as well as Director of the Baltimore Longitudinal Study on Aging. Prior to his current positions, Dr. Ferrucci served as an Associate Professor of Biology, Human Physiology, and Statistics at the University of Florence in addition to Director of the Laboratory of Clinical Epidemiology at the Italian National Institute on Aging. Dr. Ferrucci’s research primarily focuses on the causal pathways leading to progressive physical and cognitive decline in the elderly population. He has made major contributions to the implementation of various epidemiological studies conducted in both the U.S. and in Europe.

    RSVP here.

  • 9月11日:PI学术交流会 | 甘海云研究员 – 表观基因组的传递机制与合成重构
    1:30 pm-3:30 pm
    2020.09.11

    诚邀院内外学者来此学习交流

    本周五 13:30-15:30

    先进院D6环形报告厅

    详情点击这里

12
13
14
15
  • September 15: Challenges of Implementing Innovation in Drug Discovery and Development
    9:00 am-10:00 am
    2020.09.15

    Date: Tuesday, September 15, 2020
    Time: 9:00am PDT / 12:00pm EDT
    Duration: 1 hour

    The measurement of multiple biological activities following drug treatment of cell-based systems, a central tenant of phenotypic screening and profiling, is experiencing a renaissance in drug discovery as companies look beyond biochemical approaches to complex cell and tissue systems with high physiological relevance. Previously, challenges of data interpretation and limited data analytics, unclear relevance or benefit to human disease, and lack of throughput and leadership support for this approach hindered broad adoption. Many of these issues now have robust data-rich solutions, and leading scientists are reaping the benefits of an activity profiling approach. This thought leadership webinar brings together unique perspectives – from start-up to mid-size biotech and large global pharma – through discussion of challenges and achievements in implementing biomarker activity profiling strategies for pipeline progression. With audience Q&A, panelists will shed light on obvious, and less obvious, aspects of determining when a phenotypic approach can be beneficial, and how to integrate or supplement this innovation into a drug discovery and development strategy. Join Eurofins Discovery Phenotypic Center of Excellence for some serious fun.

    Key Takeaways:

    • Learn how diverse drug development companies with unique models of discovery, innovative drug modalities, and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds’ disease impact.
    • Benefit from the experiences, challenges, and successes of others in bringing phenotypic approaches to target-based drug development programs.

    Moderator:

    Alison O’Mahony, Ph.D.
    Vice President, Translational Biology
    Eurofins Discovery

    Panelists:

    Lisa Schopf, Ph.D.
    Senior Director
    Pfizer

    Stephanie Venn-Watson, DVM, MPH
    Co-Founder, Chief Executive Officer
    Epitracker

    Kieron Edwards, MBA, Ph.D.
    Chief Scientific Officer
    Sibelius

    Click here to RSVP

  • 9月15日:在药物发现和开发中实施创新的挑战
    9:00 am-10:00 am
    2020.09.15

    日期: 星期二, 9月15, 2020
    时间:上午9点

    对基于细胞的系统进行药物处理后的多种生物活性的测量,是表型筛选和剖析的核心宗旨,随着公司将目光从生化方法转向具有高度生理相关性的复杂细胞和组织系统,药物发现正在经历复兴。 此前,数据解释和有限的数据分析的挑战,与人类疾病的相关性或利益不明确,以及缺乏吞吐量和领导层的支持,阻碍了这种方法的广泛采用。 这些问题中的许多问题现在都有强大的数据丰富的解决方案,领先的科学家正在收获活动剖析方法的好处。 这个思想领导力网络研讨会通过讨论管道进展中实施生物标志物活性剖析策略的挑战和成就,汇集了独特的观点–从初创企业到中型生物技术公司和大型全球制药公司。 通过观众的问答,小组成员将阐明确定表型方法何时能带来益处的显而易见和不太显而易见的方面,以及如何将这种创新整合或补充到药物发现和开发战略中。 加入Eurofins Discovery Phenotypic卓越中心,享受一些乐趣。

    主要内容:

    • 了解具有独特发现模式、创新药物模式和非传统/天然产品来源材料的不同药物开发公司如何利用表型筛选和剖析来了解其化合物的疾病影响。
    • 从其他人将表型方法引入基于靶点的药物开发项目的经验、挑战和成功中获益。

    主持人简介:

    Alison O’Mahony, Ph.D.
    Vice President, Translational Biology
    Eurofins Discovery

    小组成员:

    Lisa Schopf, Ph.D.
    Senior Director
    Pfizer

    Stephanie Venn-Watson, DVM, MPH
    Co-Founder, Chief Executive Officer
    Epitracker

    Kieron Edwards, MBA, Ph.D.
    Chief Scientific Officer
    Sibelius

16
17
  • 9月17-19日:第四届中国生物诊断高峰论坛
    All day
    2020.09.17-2020.09.19

    在过去的半年多时间里,突如其来的新型冠状病毒疫情暴发,对人类健康和正常生活造成了巨大的危害和影响。值得肯定的是,被誉为医生“眼睛”的体外诊断试剂,特别是高通量测序技术、核酸检测以及作为补充诊断的抗体检测技术,在本次疫情的病原学确认、临床实验诊断及防控决策中发挥了前所未有的作用。

    为了及时交流经验、进一步全面提升应对未来突发公共卫生事件的应急反应和处置能力与水平。在中国食品药品检定研究院的直接参与和鼎力支持下,中国医药生物技术协会生物诊断技术分会定于2020年9月17-19日,在贵州省贵阳市举办以“施精准体外诊断、助科学决策防控”为主题的《第四届中国生物诊断高峰论坛》。

    本次论坛将邀请中国食品药品检定研究院、国家卫生健康委临床检验中心等部门的领导和防控一线专家,以及国内从事体外诊断技术与产品研发与应用的专家学者等发表主旨演讲,并以现场互动方式与参会代表开展直面沟通和交流。

    热忱欢迎生物诊断领域广大同行光临大会,携手共谋我国体外诊断技术与产业不断发展和进步。为助力实现“健康中国”的国家战略,积极奉献聪明才智。

    会议议题:

    本届大会将就以下热点开展广泛深入的研讨和交流。其中包括:体外诊断试剂相关政策法规解读;突发急性传染病体外检测试剂国家参考品的研究与质量控制要点;突发急性传染病病原学检测与溯源;高通量测序的应用与质控;核酸检测与抗体检测技术在抗疫实践中的应用与存在的问题;体外诊断试剂关键原材料制备及思考;临床实验室应急检测能力与操作安全;传统与新发输血传染病病原学筛查与输血安全等。

    组织架构:

    主办单位:中国医药生物技术协会生物诊断技术分会 

    协办单位:贵州安康医学检验中心

    承办单位:苏州华益美生物科技有限公司

    支持单位:

    中国食品药品检定研究院

    中国微生物学会生物制品专业委员会

    北京医学会检验学会医学实验室与诊断产品质量管理分会

    合作媒体:小桔灯网

    会议地点:

    贵阳市观山湖区林城西路95号,贵阳盘江诺富特饭店

    会议时间:

    2020年9月17日全天报到,9月18-19日大会学术交流。

    参会注册:

    请登录大会网站http://www.china-ivd.org,办理注册登记          

    注册费用:

    出席会议的企业代表每位缴纳会务费1200元、其他领域代表每位1000元、在读研究生可凭证优惠为每位600元,会员单位可享受9折优惠。会议食宿统一安排,费用自理。

    详情点击这里

  • September 17: The Shifting Healthcare Tech Landscape in a Post COVID-19 Era
    11:30 am-12:30 pm
    2020.09.17

    Connect with JLABS @ Shanghai residents! As part of AmCham China’s 2020 Technology and Innovation Summit, Johnson & Johnson Innovation will host a dialogue on the Shifting Healthcare Tech Landscape in the Post COVID-19 Era. Featuring three CEOs from our resident company portfolio, the presentations and panel discussion will unpack their perspectives on the changes we may see to the industry post-pandemic. 

    Register now.

  • 9月17日:AI助医 转型突围
18
  • 9月18日:CHIC Showcase #3企业家在线路演
    9:00 am-12:00 pm
    2020.09.18

    鉴于COVID-19带来的商业变局,我们将开启新的CHIC在线路演系列,为您带来高素质的企业家和经验丰富的风险投资家。本次会议是由英国驻上海总领事馆赞助,旨在促进英国生物技术/医疗健康公司在中国的业务发展。

    本月在线路演将于9月18日周五北京时间上午9:00(美国时间8月17日,9:00pm EST / 6:00pm PST)举行,为您带来4家正在寻求资金的最具发展潜力的生命科学/生物技术公司,这些公司将通过CHIC组委会的严格审查程序而选出。

    9月路演公司名单

    Vaccitech

    旨在催生T细胞免疫疗法来预防传染疾病及癌症

    Exscientia

    世界领先的人工智能药物研发公司

    Mereo BioPharma

    已完成治疗慢阻肺(COPD)急性加重药物(Acumapimod)的二期临床试验

    Owlstone Medical

    开发了具有革命性意义的呼气分析仪(Breath Biopsy),用于早期筛查危及生命的疾病

    点击这里报名

  • 9月18日:疫情趋稳下国内医疗企业发展
    8:00 pm-8:40 pm
    2020.09.18

    直播大纲:

    1.上半年医疗器械注册整体情况图鉴:境内同比增长67.9% ,进口下降75%;

    2.境内医疗器械注册数据分类解读,分地域解读:长三角和珠三角各具优势;

    3.抗疫类医疗器械注册“地图”解读:疫情应急注册谁在领跑?

    4.疫情趋稳下国内医疗器械产业发展趋势五大预判。

    点击这里查看活动详情

19
  • 2020年9月19-20日:2020中国疫苗创新论坛
    All day
    2020.09.19-2020.09.20

    为促进我国新冠疫苗的研发进度,解决临床研究中存在的问题和可能面临的风险挑战,中国疫苗行业协会泰州医药高新技术产业园区管理委员会计划在第十一届医博会期间组织举办“2020中国疫苗创新论坛”。

    一、活动内容

    主题:2020中国疫苗创新论坛

    二、活动时间

    2020年9月19-20日

    三、活动地点

    中国医药城会展中心W2馆1楼会议室

    四、组织机构

    主办方:中国疫苗行业协会

                   泰州医药高新技术产业园区管理委员会

    承办方:中国疫苗行业协会疫苗临床研究分会

                   博纳西亚医药科技有限公司

    协办方:泰州医药高新区高层次人才联谊生物制品分会

    五、活动议程

    1. 报到

    时间:2020年9月18日 14:00-20:00

    地点:中国医药城会展中心W2馆1楼

    点击这里报名

  • 9月19-20日:乘风破浪IPO:生物新技术公司的成功之路
    All day
    2020.09.19-2020.09.20

    未来“同写意大学”会是怎样的课程安排?如何帮助Biotech公司创始人尽快完成从创业到成功上市,便是本次论坛活动的初衷。

    生物科技的飞速发展造就了众多的科技公司成功上市,也推动了基于生物新技术的创新创业潮的到来。站在前沿技术的风口是Biotech公司的立业之本,然而从技术到管理到经营,再到资本化,科学家的创业之路需要在不断的学习和摔打中完成从科学家向董事长/CEO的进化。

    本次论坛活动,邀请了6位具有方向性的前沿技术Biotech公司创始人,介绍如何基于这些技术进行新药开发。同时邀请了多位成功的创业者和投资人分享和讲解创新创业上市中的关键问题。

    作为同写意持续的研发领袖社交圈活动,会前半天邀请与会报告嘉宾,Biotech公司创始人/CEO,同写意会员机构董事长人/CEO到宁波杭州湾国家湿地公园进行写意交流,在“诗和远方”中激发创新的能量与智慧。

    同写意论坛发起人 程增江

    点击这里报名

20
21
  • September 21: Discuss, Deploy, or Defer: New Technologies in Real World Biopharmaceutical Manufacturing
    All day
    2020.09.21

    10:30am ETDiscuss, Deploy, or Defer: New Technologies in Real World Biopharmaceutical ManufacturingJeff Baker – Deputy Director, Office of Biotechnology Products, FDAThis is an exciting time in the development of new biopharmaceutical healthcare solutions driven by unprecedented understanding of biomolecular mechanisms, supporting analytics, applications of machine learning and artificial intelligence, new materials, container closure systems and delivery devices, and even advanced robotics. Nevertheless, the technologies actually used in commercial biopharmaceutical manufacturing in the United States have changed very little in the last 20 years with the majority of those changes resulting from incremental optimization. This talk will discuss possible root causes giving rise to this situation.

    11:05am ETDelivering an Entirely New Class of Medicines: From Rare Disease to COVID-19John Maraganore – CEO, Alnylam PharmaceuticalsAlnylam is working to get its third drug approved in three years. This talk will discuss the journey in bringing these therapies to market, building an effective pipeline, and developing a new class of medicines in 2020.
    11:45am ETNetworking
    Utilize our networking app to view the entire attendee list, request and schedule meetings, host presentation materials and content assets, watch the full recording post-event, and access prior, during, and 60 days after the event. 
    1:00pm ETR&D During a Pandemic – An Unprecedented Collaboration
    Yvonne Greenstreet – Chief Operating Officer, Alnylam Pharmaceuticals
    Dhavalkumar Patel – Executive Vice President & Chief Scientific Officer, UCB
    Andrew Plump – President, Research & Development, Takeda
    Dave Reese – Executive Vice President, Research and Development, AmgenIn the race to develop treatments for COVID-19, it will take unprecedented collaboration on a global scale that has never been done before. One such collaboration was the COVID R&D Alliance, made up of leading biopharma companies with the common goal of accelerating R&D by evaluating therapeutic candidates and developing innovative clinical trials. This panel will cover how real-world data is advancing COVID-19 treatments, the current clinical trials underway and how they were able to speed up the process, lessons learned from pooling collective knowledge and experiences, and how collaboration has shaped the response to COVID-19.
    2:00pm ETA Fireside Chat with Michelle McMurry-Heath – President & CEO, BIO
    Dr. McMurry-Heath has joined BIO at a critical time in life sciences history. With a wealth of knowledge and experience ranging from large pharma, the FDA, and her work in academia, she has championed clinical trial evolution and the use of real-world evidence in product evaluation, promoted personalized medicine, and bolstered international preparation for pandemic disease threats. In a fireside chat with Dan Stanton, Xconomy’s managing editor, she’ll discuss how her experiences have helped her guide BIO in navigating COVID-19, promote a diverse and inclusive workforce, and keep the momentum of the industry moving forward with the most important thing in mind: delivering quality patient outcomes.

    More info

22
  • September 22-24: Oncology Virtual Partnering
    All day
    2020.09.22-2020.09.24

    During three days of face to face online meetings, leading researchers, top biotechs and biopharmaceutical companies will meet, network and partner to accelerate oncology pipelines and bring new treatment options to patients worldwide.

    About this conference

    Where the best science in oncology comes to meet

    Oncology is one of the most challenging areas for research and development, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward.

    At Inova, our aim is to facilitate the bridge between science and business. Together with BIO, we are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 22 – 24 September, researchers, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses, pitch ideas and partner to prioritize the most promising research efforts.

    This event will leverage Inova and BIO’s biopharma industry expertise, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide.

    RSVP here.

  • 9月22-23日:IVD 产业投资与并购CEO论坛
    All day
    2020.09.22-2020.09.23

    2020年由CHC医疗咨询、IVD及精准医疗产业与投资联盟主办、安亭健康医疗产业集聚区协办的“第七届中国IVD产业投资与并购CEO论坛暨IVD及精准医疗产业与投资联盟年会”将于9月22-23日上海颖奕皇冠假日酒店召开。

    活动详情及报名点击这里

  • 9月22日:2020中国医药创新与投资大会(CBIIC)暨加拿大路演专场
    9:30 am-12:00 pm
    2020.09.22

    2020中国医药创新与投资大会(CBIIC)即将于2020年9月27-29日在苏州金鸡湖畔召开。作为多年的合作伙伴,加拿大商务专员服务(Trade Commissioner Service)与大会主办方共享搭建生命科学行业交流合作国际化平台、创造医药产业跨境合作机遇的战略视角。为了更高效、精准把握全球疫情背景和挑战下的行业脉搏,在沿袭过往年度高水准的线下会议内容、主题专场以及交流洽谈元素之外,此次大会更增设将于9月22日启幕的线上加拿大路演专场,参会者在世界各地均可通过大会注册账户的在线平台深度参与,在观看企业路演、主题演讲、发起互动研讨之余能够更为充分地安排虚拟一对一合作机会。

    点击这里查看活动详情

23
  • 9月23-25日:第一届基层慢病管理论坛
    All day
    2020.09.23-2020.09.25

    当前,我国互联网+慢病管理市场正处于成长期,但已体现出相当大的优势,如实现患者的三大重要诉求,即打破依从性、场景家庭化、决策精准性;满足患者长期持续用药、定期复查、定期监测体征数据以及经验分享和饮食调节等需求。可以预见,未来互联网+慢病管理所带来的慢性病管理新模式将推动慢病管理行业发展进入新阶段。

    那么,如何提升基层慢病管理能力?2020中国诊博会以「纵横——连横纵深,拥抱基础医疗产业速变的十年」为主题,将于9月23日-9月25日在中国郑州·国际会展中心举行。

    点击这里报名

  • 9月23-25日:第三届中国诊所配套服务博览会
    All day
    2020.09.23-2020.09.25

    2020第三届中国诊博会以“纵横”为主题,将在9月23日-25日于中国·郑州举办!

    本次大会从「纵横捭阖」、「连横纵深」、「纵横驰骋」三个角度出发,关注上中下游产业协同、洞观基层医疗变革,明晰新型诊所行业前路。

    下设7场经管学术论坛峰会,5项创新实操培训,涵盖广大县域诊所、中医馆、康复诊所、慢病管理机构、民营社康/社区卫生服务中心、互联网医疗等,邀请100余位嘉宾进行干货分享,为参会者呈现一场诊所人年度盛宴!

    点击这里报名

  • Sep 23-Sep 25: virtual Future of Health
    All day
    2020.09.23-2020.09.25

    Responding to Healthcare’s Paradigm Shift
    COVID-19 has accelerated and changed the future of healthcare around the world and we’re here to help you navigate it. Join Future of Health 2020’s fully virtual event for three days of inspiring speakers, new technologies, relevant information and the most networking you’ve ever experienced in an online event.

    Due to the uncertainty about mass gatherings, we’ve moved the event to a fully virtual experience. But Future of Health 2020 won’t just be a series of Zoom presentations. Instead we’re investing in re-creating the conference experience with an online platform that brings attendees the knowledge and insights they expect from more than 100+ speakers, plus great ways to meet peers and prospects from around the world. There will be a digital expo experience, thousands of 1:1 meetings via video calls – and we can’t forget about our evening reception with entertainment.

    Read more

  • 9 月 23 日至 9 月 25 日:虚拟健康的未来
    All day
    2020.09.23-2020.09.25

    响应医疗保健范式转变
    COVID-19 加速并改变了全球医疗保健的未来,我们在此帮助您驾驭它。 加入”健康的未来2020″全虚拟活动,为期三天,提供鼓舞人心的演讲者、新技术、相关信息,以及您曾经经历过的在线活动最多的网络活动。

    由于大规模集会的不确定性,我们已将活动转移到了完全虚拟的体验中。 但《健康的未来 2020 》不会只是一系列缩放演示。 相反,我们正在投资通过在线平台重新创建会议体验,为与会者带来他们期望从 100 多名演讲者那里获得的知识和见解,以及满足世界各地同行和潜在客户的很好方式。 将有一个数字博览会的经验,成千上万的1:1的会议通过视频电话进行 – 我们不能忘记我们的晚上招待会与娱乐。

    详情请点击

  • More events
    • 9月23-25日:第一届基层慢病管理论坛
      All day
      2020.09.23-2020.09.25

      当前,我国互联网+慢病管理市场正处于成长期,但已体现出相当大的优势,如实现患者的三大重要诉求,即打破依从性、场景家庭化、决策精准性;满足患者长期持续用药、定期复查、定期监测体征数据以及经验分享和饮食调节等需求。可以预见,未来互联网+慢病管理所带来的慢性病管理新模式将推动慢病管理行业发展进入新阶段。

      那么,如何提升基层慢病管理能力?2020中国诊博会以「纵横——连横纵深,拥抱基础医疗产业速变的十年」为主题,将于9月23日-9月25日在中国郑州·国际会展中心举行。

      点击这里报名

    • 9月23-25日:第三届中国诊所配套服务博览会
      All day
      2020.09.23-2020.09.25

      2020第三届中国诊博会以“纵横”为主题,将在9月23日-25日于中国·郑州举办!

      本次大会从「纵横捭阖」、「连横纵深」、「纵横驰骋」三个角度出发,关注上中下游产业协同、洞观基层医疗变革,明晰新型诊所行业前路。

      下设7场经管学术论坛峰会,5项创新实操培训,涵盖广大县域诊所、中医馆、康复诊所、慢病管理机构、民营社康/社区卫生服务中心、互联网医疗等,邀请100余位嘉宾进行干货分享,为参会者呈现一场诊所人年度盛宴!

      点击这里报名

    • Sep 23-Sep 25: virtual Future of Health
      All day
      2020.09.23-2020.09.25

      Responding to Healthcare’s Paradigm Shift
      COVID-19 has accelerated and changed the future of healthcare around the world and we’re here to help you navigate it. Join Future of Health 2020’s fully virtual event for three days of inspiring speakers, new technologies, relevant information and the most networking you’ve ever experienced in an online event.

      Due to the uncertainty about mass gatherings, we’ve moved the event to a fully virtual experience. But Future of Health 2020 won’t just be a series of Zoom presentations. Instead we’re investing in re-creating the conference experience with an online platform that brings attendees the knowledge and insights they expect from more than 100+ speakers, plus great ways to meet peers and prospects from around the world. There will be a digital expo experience, thousands of 1:1 meetings via video calls – and we can’t forget about our evening reception with entertainment.

      Read more

    • 9 月 23 日至 9 月 25 日:虚拟健康的未来
      All day
      2020.09.23-2020.09.25

      响应医疗保健范式转变
      COVID-19 加速并改变了全球医疗保健的未来,我们在此帮助您驾驭它。 加入”健康的未来2020″全虚拟活动,为期三天,提供鼓舞人心的演讲者、新技术、相关信息,以及您曾经经历过的在线活动最多的网络活动。

      由于大规模集会的不确定性,我们已将活动转移到了完全虚拟的体验中。 但《健康的未来 2020 》不会只是一系列缩放演示。 相反,我们正在投资通过在线平台重新创建会议体验,为与会者带来他们期望从 100 多名演讲者那里获得的知识和见解,以及满足世界各地同行和潜在客户的很好方式。 将有一个数字博览会的经验,成千上万的1:1的会议通过视频电话进行 – 我们不能忘记我们的晚上招待会与娱乐。

      详情请点击

24
  • Septembe 24: REDEFINING HEALTHCARE AGILITY
    All day
    2020.09.24

    REDEFINING HEALTHCARE AGILITY
    Join for the first ever APACMed Virtual Forum
    Hear from some of the most influential leaders in Healthcare today on how they are transforming the industry ; Jose Almeida, Chairman, president and CEO of Baxter International , Kevin Lobo, CEO of Stryker and Chairman of the Advanced Medical Technology Association (AdvaMed), Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson and Dr Bernd Montag, CEO of Siemens Healthineers.
    We will bring together more than 80 world class leaders from over 30 countries to share, inspire and discuss how this is the moment for healthcare to redefine itself.
    Be inspired and get connected during the live discussions, interviews, demonstrations and master classes.
    Join us for this first ever APACMed Virtual Forum!
    Read more

  • 9月24日: 重新定义医疗保健敏捷
    All day
    2020.09.24

    重新定义医疗保健敏捷性
    加入有史以来第一个亚太虚拟论坛
    听取当今医疗保健领域一些最具影响力的领导者关于他们如何改变该行业的一些信息;百特国际董事长、总裁兼首席执行官何塞·阿尔梅达、史崔克首席执行官兼高级医疗技术协会(AdvaMed)主席凯文·洛博、全球医疗器械公司执行副总裁阿什利·麦克沃伊、强生公司首席执行官伯恩德·蒙塔格博士。
    我们将汇集来自 30 多个国家/地区 80 多名世界级领导者,分享、激励和讨论这是医疗保健如何重新定义自身的时刻。
    在现场讨论、访谈、演示和大师课程中受到启发和联系。
    加入我们有史以来第一个亚太虚拟论坛!
    详情请看

25
26
  • 9月26-27日:2020细胞免疫与基因治疗技术论坛
    All day
    2020.09.26-2020.09.27

    时间:2020年9月26-27日

    地点:上海(酒店定向通知)

    规模:350-500人

    主办单位:生物制品圈、四叶草会展

    协办单位:艾本德中国有限公司  

    媒体支持:药时空、抗体圈、生物药之家、药创客

    赞助单位:FUJIFILM富士胶片欧文科技、上海亮黑科技有限公司、上海倍谙基生物科技有限公司、上海百仑生物科技有限公司、赛思柏欧(上海)生物科技有限公司、上海吉泰依科赛生物科技有限公司、上海东富龙医疗装备有限公司、贝克曼库尔特(商贸)中国有限公司、深圳市西尔曼科技有限公司、迪必尔生物工程(上海)有限公司、三优生物医药(上海)有限公司、天俱时工程科技集团有限公司、杭州厚泽生物科技有限公司、宁波熙宁检测技术有限公司、奥星衡迅生命科技(上海)有限公司、康霖生物科技(杭州)有限公司、上海哲罗姆生物科技有限公司、泰州市百英生物科技有限公司

    点击这里报名

27
28
29
30
October
October
October